Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors

Research output: Contribution to journalArticle


To discuss the potential benefit of a chemotherapy regimen including etoposide (etoposide, cisplatin, epirubicin [EPE]), the authors report a single-institutional experience regarding 13 children with hepatoblastoma (HB) and 7 with hepatocellular carcinoma (HCC). Chemotherapy achieved partial response in 8/9 HB and in 4/5 HCC. Eight initially unresectable HB subsequently had liver resection. Event-free survival and overall survival at 5 years were 84 and 88% for HB (non-metastatic cases: 91 and 100%), 29% for HCC. EPE chemotherapy seems to be effective in the treatment of childhood malignant liver tumors. Etoposide could be suggested as part of intensive multidrug regimens for HCC and high-risk HB.

Original languageEnglish
Pages (from-to)189-198
Number of pages10
JournalPediatric Hematology and Oncology
Issue number3
Publication statusPublished - Apr 2005


  • Chemotherapy
  • Cis platin
  • Epirubicin
  • Etoposide
  • Hepatoblastoma
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors'. Together they form a unique fingerprint.

  • Cite this